CSL Limited has named Deborah Waterhouse as its Chief Executive Officer and Managing Director, closing a search that has kept the Melbourne headquartered biotechnology group under interim leadership for much of the year. The appointment was announced on 21 October 2026 and takes effect from February 2027.
Waterhouse joins from GSK, where she has been Chief Executive Officer of ViiV Healthcare since 2017 and serves as President of GSK Global Health. ViiV Healthcare is a joint venture majority owned by GSK with Shionogi as a shareholder, and it is one of the few pharmaceutical businesses in the world built around a single therapeutic area. Running it has given her close to a decade in a specialist, science led franchise that has to defend a strong market position against generic competition, which is a fair description of parts of the CSL portfolio as well.
Her career at GSK spans both commercial and country leadership. She has led the company's United States vaccines business and its United States primary care business, and she was General Manager for Australia and New Zealand between 2008 and 2012. That Australian posting matters for the reception of this hire. CSL is one of the largest companies on the Australian Securities Exchange and a national champion in a country that takes a close interest in who runs its listed flagships, and the board has chosen someone who has already run a business there.
Dr Brian McNamee, CSL Chair, said the company's next chief executive would need the ability to continue the momentum of its commercial performance, and described Waterhouse as an outstanding global leader with a proven ability to grow complex businesses. Waterhouse called CSL one of the great companies in its industry and pointed to the staff who collect plasma at the donation centres and to those who develop and manufacture its medicines and vaccines.
The transition is orderly rather than abrupt. Gordon Naylor has been serving as Interim Chief Executive Officer and Managing Director and continues in the role until the handover, after which he returns to the CSL board as a non-executive director. That is a useful arrangement, because it keeps institutional memory inside the boardroom rather than losing it at the door, and it gives an incoming chief executive a colleague who knows where the problems are buried.
For investors the question is what a GSK trained commercial leader does with a business whose principal challenge has looked operational rather than scientific. The plasma collection network, the cost base and the pace at which research converts into marketed products have all drawn scrutiny, and a period of interim leadership was never going to settle any of them. Waterhouse arrives with a record in growing a joint venture inside a larger group, which is a different exercise from running a vertically integrated manufacturer at scale, and the board is evidently betting that commercial discipline travels.
The gap between announcement and commencement is worth noting in its own right. More than three months will pass before she takes the chair, which is a long runway in a listed company of this size. It gives the market time to form a view of her before she has made a single decision, and it gives her time to form one of CSL before she has to.
